Pentabromoethylbenzene Exposure Induces Transcriptome Aberration and Thyroid Dysfunction: In Vitro, in Silico , and in Vivo Investigations
Liping Lu,Hao Wu,Shixuan Cui,Tingjie Zhan,Chunlong Zhang,Shaoyong Lu,Weiping Liu,Shulin Zhuang
DOI: https://doi.org/10.1021/acs.est.0c03308
2020-08-24
Abstract:Pentabromoethylbenzene (PBEB), as one of the novel brominated flame retardants (NFBRs), has caused increasing public concern for health risks. Till now, information regarding potential effects of PBEB on thyroid function remains unclear. Herein, we investigated thyroid disruption of PBEB <i>in vitro</i> and <i>in silico</i> and evaluated thyroid dysfunction induced by PBEB using Sprague–Dawley rats. PBEB showed thyroid receptor (TR) β antagonistic activity with IC<sub>50</sub> of 9.82 × 10<sup>–7</sup> M in the dual-luciferase reporter gene assay and induced relative reorientation of helix 11 (H11) and H12 of the TR ligand binding domain as revealed by molecular dynamics simulations. PBEB (0.2, 2, 20 mg/kg BW/d) markedly altered the transcriptome profile of thyroid with induction of 17, 42, and 119 differentially expressed genes (DEGs) involved in thyroid hormone signaling and synthesis pathway, of which <i>transthyretin</i> and <i>albumin</i> are common DEGs. The 28-d exposure to PBEB significantly decreased the triiodothyronine level (from 7.23 to 5.67 ng/mL) and increased the thyrotropin level (from 7.88 to 12.86 mU/L) for female rats. PBEB consequently reduced thyroid weight and altered its morphology with more depleted follicles. Overall, our study provides the first account of evidence on PBEB exerted thyroid disruption, transcriptome aberration, and morphological alteration, facilitating health risk assessment of PBEB and structurally related NBFRs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.est.0c03308?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.est.0c03308</a>.Table S1, decomposition of binding free energies of PBEB (kcal mol<sup>–1</sup>); Table S2, top expressed molecules identified by DEGs after exposure to PBEB at 0.2, 2, and 20 mg/kg BW/d; Table S3, primers used for qPCR of rat thyroid; Figure S1, cell viability after PBEB exposure presented as percentage response in comparison to DMSO control; Figure S2, standard curve and agonistic activity determined using dual-luciferase reporter gene assay; Figure S3, binding mode of PBEB and C alpha RMSD along 100 ns MD trajectory; Figure S4, scatter plot of DEGs in PBEB and T3 treated groups; Figure S5, overlap of DEGs and unique DEGs after PBEB treatment; Figure S6, cluster analysis of DEGs relevant to "thyroid" function for treated group with PBEB at 20 mg/kg BW/d; Figure S7, KEGG enrichment pathway analysis of DEGs relevant to "thyroid" function for treated group with PBEB at 20 mg/kg BW/d; Figure S8, GO enrichment pathway analysis of DEGs relevant to "thyroid" function for treated group with PBEB at 20 mg/kg BW/d; Figure S9, TG and TPO levels in SD rats serum after 28-d PBEB exposure; Figure S10, relative thyroid epithelial height and thyroid colloid area in SD rats after 28-d PBEB exposure; Figure S11, rat body weights after 28-d exposure to PBEB; and Figure S12, relative visceral weights of pituitary, liver, and heart after 28-d PBEB exposure (<a class="ext-link" href="/doi/suppl/10.1021/acs.est.0c03308/suppl_file/es0c03308_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
environmental sciences,engineering, environmental